1. Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer
- Author
-
Xuyang Xiao, Erlin Zhao, Xuan Zhou, Likun Wang, and Ting Jin
- Subjects
Adult ,Male ,Oncology ,hyaluronic acid-gadolinium sesquioxide-nanoparticles (ha-gd2o3-nps) ,medicine.medical_specialty ,Lung Neoplasms ,non-small cell lung cancer (NSCLC) ,Gadolinium ,Bioengineering ,Applied Microbiology and Biotechnology ,Random Allocation ,Epidermal growth factor ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Humans ,Medicine ,Hyaluronic Acid ,Particle Size ,clinic ,epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) ,Lung cancer ,Protein Kinase Inhibitors ,Survival rate ,Aged ,Neoplasm Staging ,non-small cell lung cancer (nsclc) ,business.industry ,Kinase ,Drug Synergism ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,respiratory tract diseases ,Treatment Outcome ,Drug Resistance, Neoplasm ,Case-Control Studies ,Nanoparticles ,Female ,Gadolinium oxide ,Non small cell ,Radiotherapy, Conformal ,business ,TP248.13-248.65 ,Research Article ,Research Paper ,Biotechnology ,Epidermal growth factor receptor tyrosine kinase - Abstract
It was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV EGFR mutant NSCLC diagnosed in the First Affiliated Hospital of Jinzhou Medical University were selected. They were randomly divided into the combined group (35 cases) and the control group (35 cases). HA-Gd2O3-NPs were prepared by hydrothermal polymerization, and combined with EGFR-TKI in the clinical treatment of NSCLC. The results showed that HA-Gd2O3-NPs were spherical with a uniform particle size of about 124 nm. The NSCLC survival rate of the combined group was 37.2 ± 5.3% under 6 Gy X-ray irradiation, and that of the control group was 98.4 ± 12.6% under 6 Gy X-ray irradiation. The total effective rate of the control group (20%) was significantly lower than that of the study group (42.86%) (P
- Published
- 2021